May 7th 2024
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
First-Line Tremelimumab ± Durvalumab Misses ORR End Point in Biliary Tract Cancer
September 30th 2022Results from the phase 2 IMMUCHEC trial indicated that tremelimumab with or without durvalumab did not meet the primary end point of improved objective response rate vs chemotherapy in patients with treatment-naïve biliary tract cancer.
Clinical Benefit of Trastuzumab Deruxtecan Sustained in Metastatic Gastric/GEJ Cancer
September 10th 2022Long-term follow-up of the phase 2 DESTINY-Gastric02 study revealed fam-trastuzumab deruxtecan-nxki continues to show promise in locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Tislelizumab Plus Chemo Yields Survival Benefit Vs Chemo in Advanced ESCC
July 7th 2022The phase 3 RATIONALE 306 trial showed improved overall survival for patients receiving tislelizumab plus chemotherapy vs placebo and chemotherapy for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 status.
IMU-131 Plus SOC Improves OS Vs SOC Alone in Advanced/Metastatic Gastric or GEJ Cancer
June 28th 2022Results from the phase 2 HERIZON study identified improved overall survival for patients treated with IMU-131 plus standard of care vs standard of care alone in advanced or metastatic gastric or gastroesophageal junction cancer.
Encouraging pCR Reported With Pembrolizumab Plus Chemo for Resectable Gastric, GEJ Adenocarcinoma
April 11th 2022Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.